JCO precision Oncol: a new view of prostate cancer treatment

May 22, 2019 / BIOON / - a study recently published in the Journal of clinical oncology precision Oncology (ASCO) summarizes the results of the largest genome analysis of advanced prostate cancer to date Using CGP, we analyzed thousands of tumor samples from patients with advanced prostate cancer The researchers found that 57% of the evaluated samples had the genomic characteristics indicating that these tumors were candidates for targeted treatment Photo source: JCO precision oncology, according to the American Cancer Society, prostate cancer is the most common type of cancer in men About one in nine men has been diagnosed with prostate cancer in their lifetime Due to the early diagnosis technique, the five-year survival rate of patients without distal metastasis of prostate cancer is close to 100%, while the five-year survival rate of men who have spread prostate cancer to the distal part of the body is only 30% The purpose of this study, led by the Foundation Medicine of the University of Utah and the Huntsman Cancer Institute (HCI), is to analyze prostate cancer using CGP to determine genomic changes and provide information for potential targeted treatment strategies CGP analyzes tumor samples to determine genomic changes so that patients can match available targeted therapies when possible Dr Jon Chung, deputy director of medical clinical development of the foundation, said: "this study shows that the comprehensive genome map can often recognize the changes of genome in routine clinical use, so as to provide targeted treatment programs and potential treatment development targets for patients with advanced or metastatic prostate cancer "The researchers analyzed nearly 3500 unique tumor samples, of which 1660 were primary tumors and 1816 were metastatic tumors from mismatched patients Researchers used foundation medicine's foundation one test for CGP "This is the largest study of its kind completed so far, which is very encouraging news because more than half of the patients studied have existing drug targets for their tumors "Said neeraj Agarwal, MD, a HCI prostate cancer clinician at the University of Utah "This information provides important insights into how we can design new clinical trials or drugs to better treat advanced prostate cancer "Agarwal and Chung work with scientists from eight other institutions around the world The team expects the findings to be used to accelerate the development of new drugs and therapies for advanced prostate cancer patients, including immunotherapy Reference materials: Jon h Chung et al, prospective comprehensive genetic profiling of primary and metastatic protocol tumors, JCO precision Oncology (2019) Doi: 10.1200/po.18.00283